Innovative Medicine
Backed by the Power of
BioXcel Therapeutics, Inc. is a
biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence approaches.
Innovative Medicine
Backed by the
Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D Economics
- Shortens Development Timelines
- Increases Probability of Success
AI-based Drug Development
Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug identification and development
Neuroscience
Immuno-Oncology
Nov 30, 2023
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023VIEW RELEASE
Nov 14, 2023
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial ResultsVIEW RELEASE
Nov 08, 2023
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma PhenotypeVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Dec 01, 2023 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
3.89
CHANGE
0.09 (2.37%)
